The Milwaukee Business Journal highlighted Foley’s work on behalf of the Wisconsin Economic Development Corporation in connection with Foxconn’s planned megacampus in Racine County, Wisconsin in the article, “WEDC Reveals Payment to Outside Counsel Foley & Larder for Foxconn Project.”
A WEDC spokesperson told the Business Journal that the Foxconn investment in Wisconsin is by far the largest economic development project in the state’s history, involving several international entities. “As a result, WEDC engaged with Foley & Lardner to ensure the contract clearly outlined the terms of the agreement negotiated between the parties with a specific emphasis on ensuring the state’s ability to enforce and collect on any potential clawbacks.”
A WEDC spokesperson told the Business Journal that the Foxconn investment in Wisconsin is by far the largest economic development project in the state’s history, involving several international entities. “As a result, WEDC engaged with Foley & Lardner to ensure the contract clearly outlined the terms of the agreement negotiated between the parties with a specific emphasis on ensuring the state’s ability to enforce and collect on any potential clawbacks.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”